glp 1 ag GLP-1 and Anesthesia: Considerations and Cautions for CRNAs Frontiers | Mechanisms of action
Description
But understanding potential issues helps you troubleshoot quickly if something feels off
Headache has been reported in 4%25% of patients using GLP-1 RAs 13
In clinical trials, people taking Contrave lost an average of about 8% of their initial body weight after 56 weeks, compared to less than 2% in those who took a placebo (inactive medicine)
[PubMed] Capehorn MS, Catarig AM, Furberg JK, et al
Toujeo is a pregnancy risk category C, according to the US Food and Drug Administration (FDA)
It's called retatrutide, and it's a triple-agonist medication, which means it acts on three different receptors in the body
